Trials / Withdrawn
WithdrawnNCT01502488
Adipose Derived Stem Cell Therapy for Autism
An Open-label, Non-Randomized, Multi-Center Study to Assess the Safety and Effects of Autologous Adipose-Derived Stromal Cells Delivered Intravenously in Patients With Autism
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Ageless Regenerative Institute · Industry
- Sex
- All
- Age
- 3 Years – 12 Years
- Healthy volunteers
- Not accepted
Summary
The intent of this clinical study is to answer the questions: 1. Is the proposed treatment safe 2. Is treatment effective in improving the disease pathology of patients with Autism.
Detailed description
This will be an open-label, non-randomized multi-center patient sponsored study of ASC implantation after liposuction using an IV delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered intravenously.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Fat Harvesting and Stem Cell Injection | Cells will be harvested through a local liposuction and injected via IV delivery |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2017-11-01
- Completion
- 2018-01-01
- First posted
- 2011-12-30
- Last updated
- 2017-07-21
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01502488. Inclusion in this directory is not an endorsement.